– Annual Survey has Ranked Alnylam within the Top Three on the Best Employers List Since 2019 –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its third place ranking in Science magazine’s Top Employer Survey for 2023. This marks the fifth year that Alnylam was featured as one of the top three companies in the annual survey of more than 6,800 professionals across biotechnology, biopharmaceuticals, and related industries.
“As a science-based organization, it’s critically important to us that Alnylam be regarded as a great place to work for people looking for a challenging and rewarding career at a company that is at the forefront of scientific discovery,” said Kevin Fitzgerald, Ph.D., Chief Scientific Officer. “It is equally important to us to be known for a workplace culture that makes it possible for all of our people to thrive and grow while supporting our mission to deliver transformative RNAi therapies for patients. That’s why ongoing recognition from Science magazine as a top place to work is so gratifying.”
Respondents to the web-based survey were asked to rate companies based on 24 characteristics, including innovative leadership, respect for employees, and social responsibility. Survey respondents came from all over the world with 59% from North America, 18% from Europe, and 16% from the Asia/Pacific Rim.
Alnylam’s top attributes included, “Treats employees with respect”; “Is socially responsible”; and “Has work culture values that are aligned with employee’ personal values”.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)